Related references
Note: Only part of the references are listed.Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study
A. Psyrri et al.
ANNALS OF ONCOLOGY (2012)
Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents
Gais Kadra et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Beyond taxanes: the next generation of microtubule-targeting agents
Javier Cortes et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
βII-Tubulin and βIII-Tubulin Mediate Sensitivity to Peloruside A and Laulimalide, but not Paclitaxel or Vinblastine, in Human Ovarian Carcinoma Cells
Arun Kanakkanthara et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
K. Albain et al.
LANCET (2012)
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials
Linda T. Vahdat et al.
SUPPORTIVE CARE IN CANCER (2012)
Ixabepilone development across the breast cancer continuum: a paradigm shift
N K Ibrahim
Cancer Management and Research (2012)
The role of Tau protein in resistance to paclitaxel
Marta Smoter et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer
Troels K. Bergmann et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Ixabepilone, a New Treatment Option for Metastatic Breast Cancer
Deborah L. Toppmeyer et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)
Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975
C. La Vecchia et al.
ANNALS OF ONCOLOGY (2010)
Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues
Iker Sanchez-Navarro et al.
BIOTECHNIQUES (2010)
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
Edith A. Perez et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer
Nancy Egerton
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Automated Extraction of DNA and RNA from a Single Formalin-Fixed Paraffin-Embedded Tissue Section for Analysis of Both Single-Nucleotide Polymorphisms and mRNA Expression
Guido Hennig et al.
CLINICAL CHEMISTRY (2010)
Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
Edgardo Rivera et al.
BREAST CANCER RESEARCH (2010)
The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells
Hirokuni Ikeda et al.
BREAST CANCER RESEARCH (2010)
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial
George Pentheroudakis et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer
G. Fountzilas et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial
Lajos Pusztai et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pharmacodynamics of tubulin and tubulin-binding agents: Extending their potential beyond taxanes
Eleni Andreopoulou et al.
CLINICAL BREAST CANCER (2008)
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
Eva S. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes
Neelima Denduluri et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy
Henri Roche et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer
Eva Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer
E. A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A multi-center phase II study of S-1 plus paclitaxel as first-line therapy in patients with advanced or relapsed gastric cancer
J. J. Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer
H. L. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Markers predicting clinical benefit in breast cancer from microtubule-targeting agents
L. Pusztai
ANNALS OF ONCOLOGY (2007)
Pharmacogenetics of paclitaxel metabolism
Jennifer Spratlin et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia
Tristan M. Sissung et al.
EUROPEAN JOURNAL OF CANCER (2006)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
Lisa M. McShane et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR)
JJ Lee et al.
SEMINARS IN ONCOLOGY (2005)
Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy
P Sève et al.
CLINICAL CANCER RESEARCH (2005)
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
R Rouzier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer
H Murata et al.
CANCER LETTERS (2005)
Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer
Angelo Paradiso et al.
ANNALS OF ONCOLOGY (2005)
βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability
K Kamath et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Extending survival with chemotherapy in metastatic breast cancer
J O'Shaughnessy
ONCOLOGIST (2005)
c-erbB2 and topoisomerase II alpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study
P Fritz et al.
BREAST CANCER RESEARCH (2005)
The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients
G Gifford et al.
CLINICAL CANCER RESEARCH (2004)
Epothilone B and its Analogs - A New Family of Anticancer Agents
Karl-Heinz Altmann
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2003)
Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability
H Murata et al.
ONCOGENE (2002)
Resistance to topoisomerase poisons due to loss of DNA mismatch repair
A Fedier et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Share Paper
